<DOC>
	<DOCNO>NCT02623439</DOCNO>
	<brief_summary>The primary objective determine overall survival 180 day transplantation involve HLA-haploidentical stem cell/bone marrow graft , post-transplant Cy .</brief_summary>
	<brief_title>A Study Haploidentical Bone Marrow Transplant Patients With Hematologic Malignancies</brief_title>
	<detailed_description>Study Design : This single center Phase 2 study myeloablative ( MA ) nonmyeloablative ( NMA ) conditioning , transplantation partially HLA-mismatched bone marrow peripheral blood stem cell post-transplantation cyclophosphamide ( Cy ) patient hematologic malignancy include : 1 . Acute lymphoblastic leukemia/lymphoma , acute myelogenous leukemia , Burkitt 's lymphoma remission . 2 . Relapsed lymphoma , include marginal zone B cell lymphoma , follicular lymphoma , chemotherapy-sensitive large-cell Hodgkin lymphoma . 3 . Myelodysplastic Syndrome ( MDS ) 4 . Blastic plasmacytoid dendritic cell neoplasm Primary Objective : The primary objective determine overall survival 180 day transplantation involve Myeloablative Non myeloablative conditioning , HLA-haploidentical marrow peripheral blood stem cell graft , post-transplant Cyclophosphamide GVHD prophylaxis . Secondary Objectives : Secondary objective include estimate overall progression-free survival 100 day , 180 day , one year transplantation , treatment-related mortality , incidence neutrophil platelet recovery engraftment , incidence graft failure , cumulative incidence acute chronic Graft versus Host Disease ( GVHD ) , incidence infection , cumulative incidence relapse/progression . The investigator also examine amount time transplant ( day unrelated search initiation day 0 ) .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>1 . Age : Subjects 1870 year old . 2 . Donor must 18 year age . 3 . HLA type perform high resolution . A minimum match 5 10 require . 4 . Patients must receive multiagent chemotherapy within 3 month consent date ( measure start date chemotherapy ) . 5 . Acute Leukemias . Acute Lymphoblastic Leukemia high risk 1st complete response ( CR1 ) Acute Myelogenous Leukemia high risk 1st complete response ( CR1 ) Acute Leukemias 2nd subsequent Complete Response ( CR ) Biphenotypic/Undifferentiated Leukemias 1st subsequent Complete Response ( CR ) . 6 . Burkitt 's lymphoma : second subsequent Complete Response ( CR ) . 7 . Lymphoma 8 . Patients adequate physical function 9 . Performance status : Karnofsky score 70100 % .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>hematologic malignancy</keyword>
</DOC>